Last update Jan. 21, 2021
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Long-acting benzodiazepine with anxiolytic effect. It is metabolised to N-desmethyldiazepam/nordazepam (Janbroers 1984, Pacifici 1984 y 1977).
Indicated in the control of anxiety.
Oral administration every 6 to 8 hours.
It is excreted in breast milk in small amounts, but its metabolite, N-desmethyldiazepam, has been detected in human milk at concentrations that could be significant for up to three days after a single dose (Pacifici 1977).
Its pharmacokinetic data does not make it easy to accurately predict possible transfer to breastmilk, because while its high percentage of protein binding and large volume of distribution would prevent it, the long half-life of its active metabolite (Jochemsen 1984) would facilitate it.
It has very few bibliographical references, and is marketed in few countries
The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), especially in the neonatal period and in case of prematurity because they can accumulate in the infant during chronic use (Sachs 2013).
It is advisable to monitor drowsiness and adequate feeding of the infant.
It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).
See below the information of this related product: